Clinical studies demonstrated that elevated levels of tyrosine-phosphorylated Stat3 (pStat3) in patients with stage II breast cancer correlated with an incomplete response to neo-adjuvant chemotherapy (a poor prognostic feature) [7]. The gene discussed is STAT3; the disease is breast carcinoma.